Aeglea Bio Therapeutics Inc
Change company Symbol lookup
Select an option...
AGLE Aeglea Bio Therapeutics Inc
GME GameStop Corp
XELA Exela Technologies Inc
ARKK ARK Innovation ETF
NVVEW Nuvve Holding Equity Warrants Exp 19 March 2026 *W EXP 03/19/2026
BEPH Brookfield BRP Holdings (Canada) Inc
CHKP Check Point Software Technologies Ltd
FDX FedEx Corp
VLON Vallon Pharmaceuticals Inc
HCNEU Jaws Hurricane Acquisition Corp
Go

Health Care : Biotechnology |
Company profile

Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing human enzyme therapeutics to benefit people with rare metabolic diseases. The Company’s product candidates include pegzilarginase and AGLE-177. The Company's lead product candidate, pegzilarginase, is a recombinant human arginase one that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase one Deficiency. Its engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. The Company is evaluating Pegzilarginase in a global pivotal Phase III PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and in a Phase II open-label extension study for patients with Arginase One Deficiency. Its AGLE-177, is a novel PEGylated, or polyethylene glycol modified, human enzyme engineered to reduce Homocystinuria.

Closing Price
$6.00
Day's Change
-0.17 (-2.76%)
Bid
--
Ask
--
B/A Size
--
Day's High
6.21
Day's Low
5.90
Volume
(Average)
Volume:
157,454

10-day average volume:
174,612
157,454

Shareholder Files Early Warning Report Regarding Nutritional High International Inc.

8:52 am ET September 17, 2021 (Newsfile) Print

El Cajon, California--(Newsfile Corp. - September 17, 2021) - OutCo Labs Inc. (the "Acquiror"), 8157 Wing Avenue, El Cajon, CA 92020, announced today that the Acquiror has filed an early warning report in respect of the acquisition of special warrants and common share purchase warrants in the capital of Nutritional High International Inc. (CSE: EAT) ("NHII") in connection with the transactions disclosed in the press release dated September 1, 2021 issued by NHII.

All share amounts and share prices referenced in this report are provided on a pre-20 to 1 consolidation basis. Such consolidation took place on September 2, 2021.

As a result of the completion of the transactions, OutCo Labs Inc. ("OutCo") acquired 67,340,862 Special Warrants, 40,666,667 Class A common share purchase warrants and 24,400,000 Class B common share purchase warrants.

Each special warrant entitles the holder to acquire, for no additional consideration one (1) multiple voting share (a "Multiple Voting Share") of NHII provided that the holders of common shares of NHII approve the creation of the Multiple Voting Shares on or before October 8, 2021 (the "MVS Approval Date") and otherwise ten (10) common shares in the capital of NHII ("Common Shares"), with such Special Warrants to be automatically converted forthwith after the earlier of (i) the date of the meeting of holders of Common Shares called to approve, among other things, the creation of the Multiple Voting Shares and (ii) October 8, 2021.

Each Class A Warrant entitles the holder to acquire one Common Share at any time on or before the 24 month anniversary of the closing of the Acquisition at an exercise price of Cdn$0.03. The expiry date of the Class A Warrants will be accelerated if the volume weighted average price of the Common Shares for the 10 consecutive trading days ending on the date that is 90 days following the one-year anniversary of the closing date of the Acquisition (the "Class A VWAP Date") is equal to or greater than $0.048. In such case the accelerated expiry date will bet the date that is 60 days following the Class A VWAP Date.

Each Class B Warrant entitles the holder to acquire one Common Share at any time on or before the 24 month anniversary of the closing of the Acquisition at an exercise price of Cdn$0.05. The expiry date of the Class B Warrants will be accelerated if the volume weighted average price of the Common Shares for the 10 consecutive trading days ending on the date that is 90 days following the 18 month anniversary of the closing date of the Acquisition (the "Class B VWAP Date") is equal to or greater than $0.08. In such case the accelerated expiry date will be the date that is 60 days following the Class B VWAP Date.

Assuming all of the special warrants and warrants held by the Acquiror were converted into common shares on their terms this would represent approximately 41.9%% of the issued and outstanding Common Shares.

OutCo acquired ownership of the special warrants and common share purchase warrants as consideration for the sale of assets owned by OutCo.

Prior to the completion of the transaction OutCo did not own or have direct or indirect control over any Common Shares. OutCo has a long-term view of its investment in NHII and may acquire additional securities of NHII including on the open market or through private acquisitions or sell the securities including on the open market or through private dispositions in the future depending on market conditions and other relevant factors.

This news release is issued pursuant to National Instrument 62-103 - The Early Warning System. A copy of the Early Warning Report will appear with the Company's documents on the SEDAR website at www.sedar.com.

For further information:

OutCo Labs Inc.

Telephone: 619-549-2710

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/96849

comtex tracking

COMTEX_393511364/2523/2021-09-17T08:52:42

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.